B-cell depletion by anti-CD20 (Rituximab) in renal allograft recipients who develop de novo anti-HLA allo-antibodies will result in inhibition of allo-antibody production and attenuation of chronic humoral rejection

Project: Federal Funding Agencies

Project Details

StatusFinished
Effective start/end date9/1/07 → 8/31/09

Funding

  • Brigham and Women’s Hospital